📣 VC round data is live. Check it out!

Recursion Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Recursion Pharmaceuticals and similar public comparables like Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals and more.

Recursion Pharmaceuticals Overview

About Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.


Founded

2016

HQ

United States

Employees

800

Financials (LTM)

Revenue: $75M
EBITDA: ($562M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Recursion Pharmaceuticals Financials

Recursion Pharmaceuticals reported last 12-month revenue of $75M and negative EBITDA of ($562M).

In the same LTM period, Recursion Pharmaceuticals generated $7M in gross profit, ($562M) in EBITDA losses, and had net loss of ($601M).

Revenue (LTM)


Recursion Pharmaceuticals P&L

In the most recent fiscal year, Recursion Pharmaceuticals reported revenue of $74M and EBITDA of ($559M).

Recursion Pharmaceuticals is unprofitable as of last fiscal year, with gross margin of 4%, EBITDA margin of (753%), and net margin of (868%).

See analyst estimates for Recursion Pharmaceuticals
LTMLast FY202320242025202620272028
Revenue$75M$74M$44M$58M$74M
Gross Profit$7M$3M$1M$13M$3M
Gross Margin9%4%3%23%4%
EBITDA($562M)($559M)($308M)($427M)($559M)
EBITDA Margin(754%)(753%)(701%)(730%)(753%)
EBIT Margin(813%)(873%)(798%)(819%)(873%)
Net Profit($601M)($645M)($328M)($464M)($645M)
Net Margin(806%)(868%)(748%)(793%)(868%)

Financial data powered by Morningstar, Inc.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals has current market cap of $2B, and enterprise value of $1B.

Market Cap Evolution


Recursion Pharmaceuticals' stock price is $3.51.

Recursion Pharmaceuticals share price increased by 1.4% in the last 30 days, and decreased by 16.1% in the last year.

Recursion Pharmaceuticals has an EPS (earnings per share) of $-1.21.

See more trading valuation data for Recursion Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$2B3.5%1.4%-4.4%-16.1%$-1.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Recursion Pharmaceuticals Valuation Multiples

Recursion Pharmaceuticals trades at 16.1x EV/Revenue multiple, and (2.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Recursion Pharmaceuticals

EV / Revenue (LTM)


Recursion Pharmaceuticals Financial Valuation Multiples

As of May 5, 2026, Recursion Pharmaceuticals has market cap of $2B and EV of $1B.

Recursion Pharmaceuticals has a P/E ratio of (3.1x).

LTMLast FY202320242025202620272028
EV/Revenue16.1x16.1x27.3x20.5x16.1x
EV/EBITDA(2.1x)(2.1x)(3.9x)(2.8x)(2.1x)
EV/EBIT(2.0x)(1.8x)(3.4x)(2.5x)(1.8x)
EV/Gross Profit178.8xn/mn/m90.4xn/m
P/E(3.1x)(2.9x)(5.7x)(4.0x)(2.9x)
EV/FCF(4.0x)(3.1x)(4.0x)(3.2x)(3.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Recursion Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Recursion Pharmaceuticals Margins & Growth Rates

In the most recent fiscal year, Recursion Pharmaceuticals reported gross margin of 4%, EBITDA margin of (753%), and net margin of (868%).

See estimated margins and future growth rates for Recursion Pharmaceuticals

Recursion Pharmaceuticals Margins

Last FY20242025202720282029
Gross Margin4%23%4%
EBITDA Margin(753%)(730%)(753%)
EBIT Margin(873%)(819%)(873%)
Net Margin(868%)(793%)(868%)
FCF Margin(512%)(643%)(512%)

Recursion Pharmaceuticals Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth33%27%
Gross Profit Growth928%(75%)
EBITDA Growth39%31%
EBIT Growth37%35%
Net Profit Growth41%39%
FCF Growth25%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Recursion Pharmaceuticals Operational KPIs

Recursion Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Recursion Pharmaceuticals
LTMLast FY202320242025202620272028
Rule of 40(722%)————
Bessemer Rule of X(675%)————
Revenue per Employee—$0.1M———
Opex per Employee—$0.8M———
G&A Expenses to Revenue218%238%253%305%238%
R&D Expenses to Revenue598%640%550%538%640%
Opex to Revenue—877%801%842%877%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Recursion Pharmaceuticals Competitors

Recursion Pharmaceuticals competitors include Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals, Generate Biomedicines, Harmony Biosciences, Lotus Pharmaceutical, Granules India, Cohance Lifesciences and Amylyx Pharmaceuticals.

Most Recursion Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vericel6.6x6.2x61.5x23.8x
Inhibrx Biosciences1424.5x2166.4x(14.8x)—
Galapagos(1.3x)(1.9x)(3.9x)(8.5x)
ANI Pharmaceuticals2.5x2.3x10.6x8.8x
Generate Biomedicines53.1x57.1x(8.1x)(7.2x)
Harmony Biosciences1.5x1.4x5.0x4.7x
Lotus Pharmaceutical4.8x4.1x12.2x11.7x
Granules India3.4x3.3x15.1x14.9x

This data is available for Pro users. Sign up to see all Recursion Pharmaceuticals competitors and their valuation data.

Start Free Trial

Recursion Pharmaceuticals Funding History

Before going public, Recursion Pharmaceuticals raised $435M in total equity funding, across 7 rounds.

Last private valuation of Recursion Pharmaceuticals was $1B, after raising $239M in September 2020 from Leaps by Bayer.


Recursion Pharmaceuticals Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-20Series DLeaps by Bayer$239M$1BRecursion Pharmaceuticals, a digital biology company industrializing drug discovery through an AI-guided platform combining phenotypic screening, high-resolution imaging, and deep-learning algorithms, announced a $239 million oversubscribed Series D financing round on September 9, 2020, led by Leaps by Bayer with a $50 million investment. New investors included Casdin Capital, Catalio Capital Management, Laurion Capital Management, and Samsara BioCapital, alongside existing backers such as Baillie Gifford, Mubadala, Lux Capital, Obvious Ventures, Felicis Ventures, EPIC Ventures, Two Sigma Ventures, Advantage Capital, and Intermountain Ventures. The proceeds were earmarked to support clinical development of its therapeutic pipeline, invest in drug discovery technology, double the number of clinical and preclinical programs annually, and expand capabilities including its proprietary database of cellular images from over 33 million experiments across 750+ disease models. Concurrently, Recursion entered a strategic collaboration with Bayer to discover and develop novel treatments for fibrotic diseases affecting the lung, kidney, heart, and other organs, leveraging Recursion's platform with Bayer's small molecule compound library and expertise. The deal included a $30 million upfront payment from Bayer (separate from the equity investment), potential initiation of more than ten programs, development and commercial milestone payments exceeding $100 million per program, and royalties on future sales, with Bayer holding options to exclusively license resulting therapeutics; overall deal terms were valued in excess of $1 billion. At the time, Recursion reported a pipeline of over 30 programs from early discovery to clinical stage, including four clinical-stage assets targeting diseases such as solid tumor cancers, Clostridium difficile infection, lipid storage disorders, and others across fibrosis, neurodegeneration, neuroinflammation, and oncology. The company had doubled its clinical and preclinical programs, cellular image database size, and deep-learning algorithm capabilities since its prior financing.
Jul-19Series CScottish Mortgage Investment Trust$121M$646MRecursion Pharmaceuticals is a biotechnology company using AI, machine learning, image recognition, and automation to industrialize drug discovery by conducting experimental biology at scale. Recursion's approach integrates data scientists, biologists, and engineers, led by CEO Chris Gibson, fostering a unique culture for innovation in drug development. Scottish Mortgage Investment Trust invested in Recursion in 2019, with the holding listed as Recursion Pharmaceuticals Inc Series C Pref. in their September 2019 interim financial report, valued at 40,575 (currency/unit unspecified, representing 0.5% of portfolio). The investment aligned with Scottish Mortgage's strategy of backing high-growth private companies in transformative sectors like biotech. The company went public in 2021 via IPO at $18 per share, raising proceeds before expenses of $405.8M. Scottish Mortgage continued holding post-IPO, emphasizing Recursion's potential to pursue underserved diseases profitably through AI-driven automation replacing traditional methods.
Oct-17Series BDCVC$60M—Recursion Pharmaceuticals, a biotechnology company founded in 2013 and based in Salt Lake City, Utah, combines artificial intelligence, deep learning, computer vision, and robotic automation to industrialize drug discovery. The company generates and analyzes millions of microscopic images of human cells weekly, measuring thousands of cellular features to identify differences between diseased and healthy cells and test compound responses. By 2017, Recursion had produced over 30 discovery programs across more than two dozen diseases, with lead programs slated for clinical trials in early 2018, and expanded into areas like inflammation, immuno-oncology, infectious disease, and aging. On October 3, 2017, Recursion announced a $60 million oversubscribed Series B financing round led by DCVC (Data Collective), bringing total capital raised to over $80 million following a prior $20 million Series A. Existing investors including Lux Capital (Series A lead), Obvious Ventures, Advantage Capital, Felicis, Epic, and AME participated, alongside new investors Mubadala, Menlo Ventures, CRV, Two Sigma, and high-value angels. DCVC Managing Partner Zachary Bogue joined the board, emphasizing Recursion's 'virtuous cycle' of AI-enhanced proprietary datasets for commercial-scale drug discovery in hard-to-treat diseases. The funding supported scaling Recursion's platform for clinical trials, building capabilities to address thousands of diseases, and advancing a high-resolution map of biology to reduce drug discovery time and cost. Recursion's approach positions it to potentially identify personalized treatments faster than traditional methods, owning all generated data amid competition from larger pharma players and thousands of untreated diseases. Subsequent rounds included a $121 million Series C in 2019 led by Scottish Mortgage Investment Trust and a $239 million Series D, reflecting ongoing growth in AI-driven biotech.
Nov-16Series AAME Cloud Ventures; DCVC; EPIC Ventures; Felicis; Lux Capital; Obvious Ventures$2M——
Oct-16Series AAME Cloud Ventures; DCVC; EPIC Ventures; Lux Capital; Obvious Ventures; Sahsen Ventures; Wild Basin Investments$13M—Recursion Pharmaceuticals announced its Series A funding round of $12.9 million in October 2016, led by deep technology investor Lux Capital with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments, and angel investors. The company had developed a proprietary drug discovery platform combining high-throughput biology, automation, and artificial intelligence to identify novel uses for known drugs and bioactive compounds, with an initial focus on rare genetic diseases. Series A proceeds were allocated toward developing Platform 2.0 to scale the company's research capacity from exploring dozens of targets and diseases annually to thousands. The company had already demonstrated proof of concept through partnerships with pharmaceutical partners and was in early-stage preclinical development with multiple internal programs.
Aug-14Seed—$200K——
Jan-14Pre-seed—$100K——

Recursion Pharmaceuticals M&A Activity

Recursion Pharmaceuticals has acquired 4 companies to date.

Last acquisition by Recursion Pharmaceuticals was on August 8th 2024. Recursion Pharmaceuticals acquired Exscientia for $688M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Recursion Pharmaceuticals

Exscientia
Cyclica
Valence Discovery
Vium
Description
Exscientia is an Oxford-based precision medicine company integrating AI, machine learning, and wet-lab automation to design novel drug candidates. It has advanced seven molecules into clinical trials, including DSP-1181 for OCD and GTAEXS617 for solid tumors. Publicly traded on Nasdaq since 2021, Exscientia holds partnerships with Sanofi, Bristol Myers Squibb, and Merck KGaA. Founded in 2016, the firm operates design studios in the UK, U.S., and Japan, focusing on oncology, immunology, and neurology targets.
Cyclica was a Toronto-based AI drug discovery company acquired by Recursion Pharmaceuticals in 2021. Its MatchMaker suite employed biophysics simulations and graph neural networks to predict protein-ligand binding affinities for over 3 billion virtual compounds. The platform supported polypharmacology analysis for repurposing existing drugs and de novo design, serving clients like AstraZeneca and Pfizer in oncology and neurology programs.
Valence Discovery is a Montreal-based AI drug discovery company pioneering few-shot learning for molecular design. The platform generates novel compounds for hard-to-drug targets using structure-based and ligand-optimized models. Valence partners with pharma giants like Sanofi for multiparameter optimization pipelines. Founded in 2021, it raised $25 million in Series A funding.
Vium is a San Mateo, California-headquartered biotechnology firm founded in 2013 that advances preclinical research through digital biomarkers. Fully AAALAC accredited with commendation for the 3Rs principles, it serves biotech, pharmaceutical, academic, and drug discovery clients. The Digital Vivarium and Vium Cloud platforms employ computer vision, AI, machine learning, and sensors for non-invasive monitoring of physiological metrics and behaviors in animal studies, enhancing data accuracy and study reproducibility.
HQ CountryUnited KingdomCanadaCanadaUnited States
HQ City
Oxford
Toronto
Montreal
San Francisco, CA
Deal Date8 Aug 20248 May 20238 Mar 202328 Jul 2020
Valuation$688M$40M$48M$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Recursion Pharmaceuticals acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Recursion Pharmaceuticals

When was Recursion Pharmaceuticals founded?Recursion Pharmaceuticals was founded in 2016.
Where is Recursion Pharmaceuticals headquartered?Recursion Pharmaceuticals is headquartered in United States.
How many employees does Recursion Pharmaceuticals have?As of today, Recursion Pharmaceuticals has over 800 employees.
Who is the CEO of Recursion Pharmaceuticals?Recursion Pharmaceuticals' CEO is Najat Khan.
Is Recursion Pharmaceuticals publicly listed?Yes, Recursion Pharmaceuticals is a public company listed on Nasdaq.
What is the stock symbol of Recursion Pharmaceuticals?Recursion Pharmaceuticals trades under RXRX ticker.
When did Recursion Pharmaceuticals go public?Recursion Pharmaceuticals went public in 2021.
Who are competitors of Recursion Pharmaceuticals?Recursion Pharmaceuticals main competitors include Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals, Generate Biomedicines, Harmony Biosciences, Lotus Pharmaceutical, Granules India, Cohance Lifesciences, Amylyx Pharmaceuticals.
What is the current market cap of Recursion Pharmaceuticals?Recursion Pharmaceuticals' current market cap is $2B.
What is the current revenue of Recursion Pharmaceuticals?Recursion Pharmaceuticals' last 12 months revenue is $75M.
What is the current revenue growth of Recursion Pharmaceuticals?Recursion Pharmaceuticals revenue growth (NTM/LTM) is 32%.
What is the current EV/Revenue multiple of Recursion Pharmaceuticals?Current revenue multiple of Recursion Pharmaceuticals is 16.1x.
Is Recursion Pharmaceuticals profitable?No, Recursion Pharmaceuticals is not profitable.
What is the current EBITDA of Recursion Pharmaceuticals?Recursion Pharmaceuticals has negative EBITDA and is not profitable.
What is Recursion Pharmaceuticals' EBITDA margin?Recursion Pharmaceuticals' last 12 months EBITDA margin is (754%).
What is the current EV/EBITDA multiple of Recursion Pharmaceuticals?Current EBITDA multiple of Recursion Pharmaceuticals is (2.1x).
What is the current FCF of Recursion Pharmaceuticals?Recursion Pharmaceuticals' last 12 months FCF is ($298M).
What is Recursion Pharmaceuticals' FCF margin?Recursion Pharmaceuticals' last 12 months FCF margin is (399%).
What is the current EV/FCF multiple of Recursion Pharmaceuticals?Current FCF multiple of Recursion Pharmaceuticals is (4.0x).
How many companies Recursion Pharmaceuticals has acquired to date?As of May 2026, Recursion Pharmaceuticals has acquired 4 companies.
What was the largest acquisition by Recursion Pharmaceuticals?$688M acquisition of Exscientia on 8th August 2024 was the largest M&A Recursion Pharmaceuticals has done to date.
What companies Recursion Pharmaceuticals acquired?Recursion Pharmaceuticals acquired Exscientia, Valence Discovery, Cyclica, and Vium.
In how many companies Recursion Pharmaceuticals has invested to date?Recursion Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Recursion Pharmaceuticals

Lists including Recursion Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial